keyword
MENU ▼
Read by QxMD icon Read
search

Ivabradine AND Heart failure

keyword
https://www.readbyqxmd.com/read/29300199/recent-advances-in-heart-failure
#1
Mahwash Kassi, Bashar Hannawi, Barry Trachtenberg
PURPOSE OF REVIEW: Acute heart failure continues to be a challenge as there is limited benefit of numerous agents that have been tested. Cardiac resynchronization therapy remains standard of care, yet timing and need for implantable cardiac defibrillator has been brought into question with the recent randomized trials. Several recent advances have been made towards management of heart failure both in drug and device therapy. The purpose of this review is to provide an update on the most important recent studies on heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF)...
January 2, 2018: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/29276898/-clinical-and-demographic-characteristics-of-an-outpatient-russian-population-with-chronic-heart-failure-at-the-time-of-enrollment-in-the-qualify-registry-for-evaluating-consistency-with-clinical-guidelines-on-drug-therapy
#2
S N Tereshchenko, I V Zhirov, A A Petrukhina
BACKGROUND: Chronic heart failure is the most common condition in patients with cardiovascular diseases. Therefore, evaluating consistency of doctor's recommendations with guidelines on drug therapy is a relevant issue. AIM: To evaluate consistency of doctor's recommendations with guidelines on drug therapy for CHF. MATERIALS AND METHODS: The study presents enrollment visit data for the Russian part of the international prospective registry, QUALIFY...
2017: Kardiologiia
https://www.readbyqxmd.com/read/29251762/drug-action-s-drug-marketing-and-clinical-medicine-suppression-of-ventricular-arrhythmogenicity-with-if-blockade-in-human-heart-failure-emerging-clinical-evidence-for-ivabradine-treatment-benefit-beyond-heart-rate-control
#3
https://www.readbyqxmd.com/read/29249470/heart-rate-as-a-prognostic-marker-and-therapeutic-target-in-acute-and-chronic-heart-failure
#4
Fabrizio Oliva, Paola Sormani, Rachele Contri, Carlo Campana, Valentina Carubelli, Antonio Cirò, Fabrizio Morandi, Giuseppe Di Tano, Andrea Mortara, Michele Senni, Marco Metra, Enrico Ammirati
Since increased heart rate (HR) is associated with higher mortality in several cardiac disorders, HR is considered not only a physiological indicator but also a prognostic and biological marker. In heart failure (HF), it represents a therapeutic target in chronic phase. The use or up-titration of beta-blockers, a milestone in HF with reduced left ventricular ejection fraction (LVEF) treatment, is at times limited by patients' hemodynamic profile or intolerance. Ivabradine, a HR-lowering drug inhibiting the f-current in pacemaker cells, has been shown to improve outcome in patients with chronic HF, in sinus rhythm with increased HR beyond beta-blocker therapy...
December 14, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29239349/influences-of-ivabradine-treatment-on-serum-levels-of-cardiac-biomarkers-sst2-gdf-15-supar-and-h-fabp-in-patients-with-chronic-heart-failure
#5
Peter Jirak, Dzeneta Fejzic, Vera Paar, Bernhard Wernly, Rudin Pistulli, Ilonka Rohm, Christian Jung, Uta C Hoppe, P Christian Schulze, Michael Lichtenauer, Atilla Yilmaz, Daniel Kretzschmar
Chronic heart failure (CHF) represents a major cause of hospitalization and death. Recent evidence shows that novel biomarkers such as soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR) and heart-type fatty acid binding protein (H-FABP) are correlated with inflammatory and ischemic responses in CHF patients. In this study we examined the effects of Ivabradine that inhibited the hyperpolarization-activated cyclic nucleotide-gated channel (HCN channel, also called funny current If), thereby leading to selective heart rate reduction and improved myocardial oxygen supply on the cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in 50 CHF patients at the University Hospital of Jena...
December 14, 2017: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/29225577/if-channel-as-an-emerging-therapeutic-target-for-cardiovascular-diseases-a-review-of-current-evidence-and-controversies
#6
REVIEW
Hayelom G Mengesha, Tadesse B Tafesse, Mohammed H Bule
In 2015, non-communicable diseases accounted for 39.5 million (70%) of the total 56.4 million deaths that occurred globally, of which 17.7 million (45%) were due to cardiovascular diseases. An elevated heart rate is considered to be one of the independent predictors and markers of future cardiovascular diseases. A variety of experimental and epidemiological studies have found that atherosclerosis, heart failure, coronary artery disease, stroke, and arrhythmia are linked to elevated heart rate. Although there are established drugs to reduce the heart rate, these drugs have undesirable side effects...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29183646/a-risk-score-to-predict-the-absence-of-left-ventricular-reverse-remodeling-implications-for-the-timing-of-icd-implantation-in-primary-prevention
#7
Jordi Pérez-Rodon, Enrique Galve, Carmen Pérez-Bocanegra, Teresa Soriano-Sánchez, Jesús Recio-Iglesias, Eva Domingo-Baldrich, Mila Alzola-Guevara, Ignacio Ferreira-González, Josep Ramon Marsal, Aida Ribera-Solé, Laura Gutierrez García-Moreno, Luz María Cruz-Carlos, Nuria Rivas-Gandara, Ivo Roca-Luque, Jaume Francisco-Pascual, Artur Evangelista-Masip, Àngel Moya-Mitjans, David García-Dorado
BACKGROUND: A prophylactic implantable cardioverter defibrillator (ICD) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF) is only indicated when left ventricular ejection fraction (LVEF) reassessment remains ≤35% after 3-6 months on optimal pharmacological therapy. However, LVEF may not improve during this period and the patient may be exposed to an unnecessary risk of sudden cardiac death. This study aimed to determine the incidence and predictors of the absence of left ventricular reverse remodeling (LVRR) after pharmacological treatment optimization in patients with HFrEF to design a risk score of absence of LVRR...
November 25, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/29161389/innovations-in-management-of-cardiac-disease-drugs-treatment-strategies-and-technology
#8
P Foëx
Within the last generation, the management of patients with heart disease has been transformed by advances in drug treatments, interventions and diagnostic technologies. The management of arterial hypertension saw beta-blockers demoted from first- to third-line treatment. Recent studies suggest that the goal of treatment may have to change to lower systolic blood pressures to prevent long-term organ damage. Today less than 15% of coronary revascularizations are surgical and more than 85% are done by interventional cardiologists inserting coronary stents...
December 1, 2017: British Journal of Anaesthesia
https://www.readbyqxmd.com/read/29142810/the-role-of-ivabradine-in-diastolic-heart-failure-with-preserved-ejection-fraction-a-doppler-echocardiographic-study
#9
Federico Cacciapuoti, Valerio Massimo Magro, Michele Caturano, Diana Lama, Fulvio Cacciapuoti
Background: Ivabradine (IVA) is effective in patients with coronary artery disease (CAD) or systolic heart failure in sinus rhythm. Its action consists in reducing heart rate (HR) and improving the time of left ventricular (LV) diastolic filling. The aim of this study was to evaluate the effects of IVA added to conventional therapy on patients with diastolic heart failure (DHF) and preserved ejection fraction (HFpEF). Methods: We evaluated 25 patients with DHF in the New York Heart Association (NYHA) Class II-III and sinus rhythm...
October 2017: Journal of Cardiovascular Echography
https://www.readbyqxmd.com/read/29121737/ivabradine-well-tolerated-in-elderly-patients-with-systolic-heart-failure
#10
EDITORIAL
Christos Zivlas, Paul W X Foley
No abstract text is available yet for this article.
December 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29121732/quality-of-life-improvement-in-older-patients-with-heart-failure-initiated-on-ivabradine-results-from-the-uk-multi-centre-live-life-prospective-cohort-study
#11
D Zachariah, D Stevens, G Sidorowicz, C Spooner, N Rowell, J Taylor, R Kay, M S Salek, P R Kalra
AIMS: LIVE:LIFE is a multi-centre, open-label, prospective observational cohort study assessing health-related quality of life (HRQoL) in older patients with chronic heart failure (CHF) following initiation of ivabradine. The primary endpoint is change in Minnesota Living with Heart Failure Questionnaire (MLWHFQ) total score after 6months. METHODS AND RESULTS: Consenting patients aged ≥70years with CHF, in whom ivabradine was initiated within its licensed indication, were enrolled...
December 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29098508/pharmacological-heart-rate-lowering-in-patients-with-a-preserved-ejection-fraction-review-of-a-failing-concept
#12
REVIEW
Markus Meyer, Mehdi Rambod, Martin LeWinter
Epidemiological studies have demonstrated that high resting heart rates are associated with increased mortality. Clinical studies in patients with heart failure and reduced ejection fraction have shown that heart rate lowering with beta-blockers and ivabradine improves survival. It is therefore often assumed that heart rate lowering is beneficial in other patients as well. Here, we critically appraise the effects of pharmacological heart rate lowering in patients with both normal and reduced ejection fraction with an emphasis on the effects of pharmacological heart rate lowering in hypertension and heart failure...
November 3, 2017: Heart Failure Reviews
https://www.readbyqxmd.com/read/29027608/ivabradine-in-postural-orthostatic-tachycardia-syndrome-preliminary-experience-in-children
#13
Grazia Delle Donne, Ferran Rosés Noguer, Jan Till, Tushar Salukhe, Sanjay K Prasad, Piers E F Daubeney
OBJECTIVE: Ivabradine is a selective and specific inhibitor of the I(f) current in the sinoatrial and atrioventricular nodes. It decreases heart rate and myocardial oxygen consumption at rest and during exercise. It is used in adults for management of heart failure and angina, but promising results have been obtained in postural orthostatic tachycardia syndrome (POTS). There is little experience of ivabradine in childhood, although it is used on a compassionate basis. Our aim was to review our experience of ivabradine in a retrospective evaluation of pediatric patients with POTS...
October 13, 2017: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29027329/duration-of-chronic-heart-failure-affects-outcomes-with-preserved-effects-of-heart-rate-reduction-with-ivabradine-findings-from-shift
#14
Michael Böhm, Michel Komajda, Jeffrey S Borer, Ian Ford, Christoph Maack, Luigi Tavazzi, Aurélie Moyne, Karl Swedberg
AIMS: In heart failure (HF) with reduced ejection fraction and sinus rhythm, heart rate reduction with ivabradine reduces the composite incidence of cardiovascular death and HF hospitalization. METHODS AND RESULTS: It is unclear whether the duration of HF prior to therapy independently affects outcomes and whether it modifies the effect of heart rate reduction. In SHIFT, 6505 patients with chronic HF (left ventricular ejection fraction of ≤35%), in sinus rhythm, heart rate of ≥70 b...
October 12, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28958335/the-clinical-use-of-ivabradine
#15
REVIEW
Jacob S Koruth, Anuradha Lala, Sean Pinney, Vivek Y Reddy, Srinivas R Dukkipati
The clinical use of ivabradine has and continues to evolve along channels that are predicated on its mechanism of action. It selectively inhibits the funny current (If) in sinoatrial nodal tissue, resulting in a decrease in the rate of diastolic depolarization and, consequently, the heart rate, a mechanism that is distinct from those of other negative chronotropic agents. Thus, it has been evaluated and is used in select patients with systolic heart failure and chronic stable angina without clinically significant adverse effects...
October 3, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28916091/retraction-notice-to-ivabradine-as-adjuvant-treatment-for-chronic-heart-failure-int-j-cardiol-227-2017-43-50
#16
Carolina C Mizzaci, Gustavo J M Porfírio, André T Vilela, José Cícero S Guillhen, Rachel Riera
No abstract text is available yet for this article.
November 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28903983/ivabradine-in-heart-failure-the-representativeness-of-shift-systolic-heart-failure-treatment-with-the-if-inhibitor-ivabradine-trial-in-a-broad-population-of-patients-with-chronic-heart-failure
#17
COMPARATIVE STUDY
Debraj Das, Gianluigi Savarese, Ulf Dahlström, Michael Fu, Jonathan Howlett, Justin A Ezekowitz, Lars H Lund
BACKGROUND: The sinus node inhibitor ivabradine was approved for patients with heart failure (HF) after the ivabradine and outcomes in chronic HF (SHIFT [Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial]) trial. Our objective was to characterize the proportion of patients with HF eligible for ivabradine and the representativeness of the SHIFT trial enrollees compared with those in the Swedish Heart Failure Registry. METHODS AND RESULTS: We examined 26 404 patients with clinical HF from the Swedish Heart Failure Registry and divided them into SHIFT type (left ventricular ejection fraction <40%, New York Heart Association class II-IV, sinus rhythm, and heart rate ≥70 beats per minute) and non-SHIFT type...
September 2017: Circulation. Heart Failure
https://www.readbyqxmd.com/read/28859790/ivabradine-in-children-with-dilated-cardiomyopathy-and-symptomatic-chronic-heart-failure
#18
RANDOMIZED CONTROLLED TRIAL
Damien Bonnet, Felix Berger, Eero Jokinen, Paul F Kantor, Piers E F Daubeney
BACKGROUND: Heart rate reduction as a therapeutic target has been investigated in adults with heart failure (HF). Ivabradine has shown promising efficacy, but has not been evaluated in children. Currently, treatment recommendations for chronic pediatric HF are based mainly on chronic HF guidelines for adults. OBJECTIVES: The authors explored the dose-response relationship of ivabradine in children with dilated cardiomyopathy and symptomatic chronic HF. The primary endpoint was ≥20% reduction in heart rate from baseline without inducing bradycardia or symptoms...
September 5, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28844168/effects-of-heart-rate-reduction-with-ivabradine-on-the-international-%C3%A4-ndex-of-erectile-function-iief-5-in-patients-with-heart-failure
#19
Kadir Uğur Mert, Muhammet Dural, Gurbet Özge Mert, Kemal Iskenderov, Ata Özen
INTRODUCTION: The presence of concomitant erectile dysfunction (ED) with heart failure (HF) is not surprising, because endothelial dysfunction is pathophysiologic signature of both ED and HF. ED significantly and adversely affects quality of life in patients with HF. It was demonstrated that ivabradine treatment can improve endothelial function and ED in experimental models. In this study, we aimed to determine the effect of ivabradine treatment on ED in patients with HF via International Index of Erectile Function (IIEF-5) questionaire...
August 26, 2017: Aging Male: the Official Journal of the International Society for the Study of the Aging Male
https://www.readbyqxmd.com/read/28840572/pharmacologic-management-for-heart-failure-and-emerging-therapies
#20
REVIEW
Diana H Kim, Feng-Ju Chien, Howard J Eisen
PURPOSE OF REVIEW: This review aims to summarize the growing body of literature of HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) with a focus on recent pharmacologics. RECENT FINDINGS: HFrEF continues to be more widely investigated than HFpEF. Ivabradine and combinatorial treatment with sacubitril and valsartan are promising newly approved therapies. Other experimental therapies have emerged, which include Serelaxin, Empagliflozin, Neuregulin, and Omecamtive mecarbil, among others...
August 24, 2017: Current Cardiology Reports
keyword
keyword
76071
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"